Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idarubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 10/20 | 0.71 |
| ▸ | THRB | P10828 | 10/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.71 |
| ▸ | BLM | P54132 | 9/20 | 0.71 |
| ▸ | RECQL | P46063 | 8/20 | 0.71 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | BRCA1 | P38398 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.71 |
| ▸ | HTT | P42858 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.71 |
| ▸ | USP2 | O75604 | 5/20 | 0.71 |
| ▸ | S100A4 | P26447 | 5/20 | 0.71 |
| ▸ | PAX8 | Q06710 | 5/20 | 0.71 |
| ▸ | STAT6 | P42226 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idarubicin SCHEMBL28122978 | 0.85 | MEN1 (0.94) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL27723076 | 0.85 | MEN1 (0.51) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL15159345 | 0.84 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL16606206 | 0.84 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL12257447 | 0.84 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL3750 | 0.84 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL7029978 | 0.84 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL18738468 | 0.84 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL20541733 | 0.84 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Idarubicin SCHEMBL13575798 | 0.84 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021894-A1 | SEPTIN INHIBITORS FOR TREATMENT OF CANCERS | University of Rochester (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021042022-A1 | SEPTIN INHIBITORS FOR TREATMENT OF CANCERS | UNIVERSITY OF ROCHESTER (US) | 2021-03-04 | — | — | WO | disclosed |
| US-9220714-B2 | Nitrofuran compounds for the treatment of cancer and angiogenesis | BROWN UNIVERSITY (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130331383-A1 | NITROFURAN COMPOUNDS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS | BROWN UNIVERSITY (US) | 2013-12-12 | — | — | US | disclosed |
| US-8470815-B2 | Nitrofuran compounds for the treatment of cancer and angiogenesis | BROWN UNIVERSITY (US) | 2013-06-25 | — | — | US | disclosed |
| EP-2004177-B1 | NITROFURAN COMPOUNDS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS | WOMEN AND INFANTS HOSPITAL OF RHODE ISLAND INC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110288080-A1 | Nitrofuran Compounds for the Treatment of Cancer and Angiogenesis | BROWN UNIVERSITY | 2011-11-24 | — | — | US | disclosed |
| EP-2004177-A2 | NITROFURAN COMPOUNDS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS | Women and Infants Hospital of Rhode Island Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007108947-A2 | NITROFURAN COMPOUNDS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS | WOMEN AND INFANTS HOSPITAL OF RHODE ISLAND, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288080-A1 | Nitrofuran Compounds for the Treatment of Cancer and Angiogenesis | NNMT, NQO1, NOS2 | TOP2A 1842/4885MEN1 433/4885THRB 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.